Codon Devices and Agrivida Enter into Development Agreement for Biofuel Applications.

Collaboration Marks Unveiling of Codon's BioLOGIC[TM] Engineering Partnering Program

CAMBRIDGE, Mass. -- Codon Devices, Inc., the Constructive Biology Company[TM], announced today that it has entered into an agreement with Agrivida Inc. for the discovery, development and commercialization of engineered proteins for use in biofuel applications.

This agreement represents the unveiling of Codon Devices' BioLOGIC[TM] Engineering Partnering Program under which partners can gain strategic access to the Company's proprietary development technologies. The BioLOGIC[TM] Engineering Platform combines sophisticated design algorithms with advanced assay and protein engineering capabilities to result in a revolutionary system for the rapid design, discovery and optimization of proteins for specific applications. An integral component of the BioLOGIC[TM] Engineering Platform is Codon Devices' BioFAB[TM] Production Platform which produces high quality synthetic genes at a lower cost and quicker turn-around time than ever before available.

Agrivida, an agricultural biotechnology company, is developing corn varieties optimized for producing ethanol, a clean renewable biofuel. Under the Agreement, Codon Devices will, in exchange for a royalty and performance-based payments, utilize its BioLOGIC[TM] Engineering Platform to develop enzymes optimized for use in Agrivida's proprietary ethanol production technology. Traditional methods for manufacturing ethanol make use of the corn grain only, leaving the remaining plant material, such as the corn leaves, stalks, and husks in the field. These remaining parts account for fifty percent of the total biomass yield per acre of farmland, but they cannot be economically converted into ethanol using today's technology. Central to Agrivida's ethanol-optimized corn technology are engineered enzymes that are incorporated into the corn plants themselves. These enzymes will efficiently degrade the entire mass of plant material into small sugars that can then be readily converted to ethanol. The optimized enzymes that Codon Devices will develop will allow Agrivida to further optimize the degradation process throughout the entire plant resulting in significant improvements to ethanol production.

"This collaboration underscores the value of our BioLOGIC[TM] Engineering Platform for the rapid development of superior proteins with desired properties, such as enzymes with highly specialized functions," said Brian M. Baynes, Ph.D., Chief Scientific Officer of Codon Devices. "With traditional approaches to developing such enzymes, this normally would be a one to two year project with no certainty of the outcome. In contrast, using our BioLOGIC[TM] Engineering Platform, we expect to be able to deliver these optimized enzymes to Agrivida in six to nine months."

"We have been working with Codon Devices over the past several months for our custom gene synthesis needs. We are thrilled with this new opportunity to partner with Codon and leverage its BioLOGIC[TM] Platform in our own research and development." said R. Michael Raab, Ph.D., Chief Executive Officer of Agrivida. "Codon Devices' development of these enzymes will help advance our development and commercialization of technologies that will dramatically improve ethanol production."

"This agreement demonstrates the power of Constructive Biology[TM] to accelerate research and development in important end markets such as biofuels," said John P. Danner, President and Chief Executive Officer of Codon Devices. "In addition to other biofuel applications, we anticipate that our BioLOGIC[TM] Engineering Platform will substantially accelerate development of many other important fields, such as next-generation biosecurity, improved agricultural products, and engineered vaccines and therapeutics."

About Codon Devices

Codon Devices, Inc., based in Cambridge, MA, is a privately-held biotechnology company focused on enabling commercial applications of synthetic biology. Codon Devices' proprietary synthesis and design technologies improve the productivity of its industrial, pharmaceutical and academic customers in a paradigm shift to what the Company calls Constructive Biology[TM]. The Company's focus is on developing and delivering high-value products and design services in a variety of application areas, including engineered gene libraries, engineered cells that produce novel pharmaceuticals, improved vaccines, agricultural products, and biorefineries for the production of industrial chemicals and energy. Codon Devices' BioFAB[TM] platform uses sophisticated informatics, robotics and sequencing technologies to accurately synthesize genetic codes orders of magnitude more rapidly and cost-effectively than other currently available technology. More information about Codon Devices is available at www.codondevices.com.